NFGH
TCRX icon

Nan Fung Group Holdings’s TScan Therapeutics TCRX Stock Holding History

Nan Fung Group Holdings’s Portfolio TCRX Stock Details TCRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q1 		– Sell
-48,600
Closed -$219K – 55
2021
Q4 		$219K Buy
+48,600
New +$351K 0.06% 44

Other funds holding TCRX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
DMC
Deer Management Company Larchmont, New York $622M AUM 24.27% 1-Year Est. Return
AI
Alphabet Inc Mountain View, California $4.02B AUM 215.74% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
HA
HHLR Advisors Grand Cayman, Cayman Islands $1.67B AUM 7.53% 1-Year Est. Return
DF
DC Funds Mclean, Virginia $1.49M AUM 18.57% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return

Nan Fung Group Holdings's TCRX Position: Q1 2022 in Review

Nan Fung Group Holdings sold out of TScan Therapeutics (TCRX) in Q1 2022, closing a stake of 48,600 shares — an estimated $219K sold.

Nan Fung Group Holdings first reported a position in TCRX in Q4 2021 and held it in 1 quarter. The position peaked at $219K in Q4 2021. 25 funds tracked by Wall St. Rank hold TCRX as of Q1 2022.

  • Nan Fung Group Holdings reported no remaining TScan Therapeutics position as of Q1 2022 after selling out during the quarter.
  • Nan Fung Group Holdings sold 48,600 TScan Therapeutics shares in Q1 2022, an estimated $219K.
  • Nan Fung Group Holdings first reported a position in TScan Therapeutics in Q4 2021 and held it in 1 quarter.
  • Nan Fung Group Holdings's TScan Therapeutics position peaked at $219K in Q4 2021.
  • 25 funds tracked by Wall St. Rank held TScan Therapeutics as of Q1 2022.

Based on Nan Fung Group Holdings's 13F filing for Q1 2022, filed 13 May 2022.